These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

472 related items for PubMed ID: 9107084

  • 1. Analysis of the risk of solid tumor following Hodgkin's disease.
    Maurizi Enrici R, Anselmo AP, Osti MF, Santoro M, Tombolini V, Mandelli F, Biagini C.
    Haematologica; 1997; 82(1):57-63. PubMed ID: 9107084
    [Abstract] [Full Text] [Related]

  • 2. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E, Anselmo AP, Klersy C, Santoro M, Orlandi E, Pagnucco G, Lunghi F, Maurizi-Enrici R, Baroni CD, Lazzarino M, Mandelli F, Bernasconi C.
    Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
    [Abstract] [Full Text] [Related]

  • 3. Fifteen-year experience in Hodgkin's disease: role of combined modality treatment and splenectomy in the incidence of secondary acute leukemia.
    Zinzani PL, Fiacchini M, Mazza P, Gherlinzoni F, Bocchia M, Tura S.
    Haematologica; 1991 Sep; 76(4):305-10. PubMed ID: 1724437
    [Abstract] [Full Text] [Related]

  • 4. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease.
    Brosteanu O, Hasenclever D, Loeffler M, Diehl V, German Hodgkin's Lymphoma Study Group.
    Ann Hematol; 2004 Mar; 83(3):176-82. PubMed ID: 15064867
    [Abstract] [Full Text] [Related]

  • 5. Hodgkin's disease: summary of twenty years' experience.
    Mazza P, Bocchia M, Zinzani PL, Fiacchini M, Gherlinzoni F, Bandini G, Bendandi M, Frezza GP, Neri S, Barbieri E.
    Haematologica; 1992 Mar; 77(6):487-93. PubMed ID: 1283856
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
    Niu Y, Shi YK, He XH, Feng FY, Zhou LQ, Gu DZ.
    Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
    [Abstract] [Full Text] [Related]

  • 8. Hodgkin's disease and the risk of acute leukemia in successfully treated patients.
    Valagussa P, Bonadonna G.
    Haematologica; 1998 Sep; 83(9):769-70. PubMed ID: 9825571
    [No Abstract] [Full Text] [Related]

  • 9. The risk of non-Hodgkin's lymphoma after Hodgkin's disease, with special reference to splenic treatment.
    Enrici RM, Anselmo AP, Iacari V, Osti MF, Santoro M, Tombolini V, Mandelli F, Biagini C.
    Haematologica; 1998 Jul; 83(7):636-44. PubMed ID: 9718869
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Bulky mediastinal Hodgkin's disease: results of a combined modality approach (ABVD/MOPP alternating chemotherapy plus radiation therapy).
    De Lena M, Ditonno P, Lorusso V, Timurian A, Pellecchia A, Brandi M, Berardi F, Marzullo F.
    Haematologica; 1993 Jul; 78(4):230-5. PubMed ID: 7507457
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radio-chemotherapy for Hodgkin's disease.
    Villani F, Busia A, Villani M, Laffranchi A, Viviani S, Bonfante V.
    Anticancer Res; 2009 Feb; 29(2):777-83. PubMed ID: 19331235
    [Abstract] [Full Text] [Related]

  • 14. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S, Camós M, López-Guillermo A, Bosch F, Cervantes F, Blandé J, Esteve J, Cobo F, Nomdedeu B, Campo E, Montserrat E.
    Cancer; 2000 May 01; 88(9):2142-8. PubMed ID: 10813727
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
    Harrison CN, Gregory W, Hudson GV, Devereux S, Goldstone AH, Hancock B, Winfield D, MacMillan AK, Hoskin P, Newland AC, Milligan D, Linch DC.
    Br J Cancer; 1999 Oct 01; 81(3):476-83. PubMed ID: 10507773
    [Abstract] [Full Text] [Related]

  • 17. Hodgkin's disease: controversies and challenges for the future.
    Tura S, Canellos G, Goldstone A, Longo D, McMillan A, Urba W, Zinzani PL.
    Haematologica; 1991 Oct 01; 76(4):263-79. PubMed ID: 1724436
    [No Abstract] [Full Text] [Related]

  • 18. Clinical dose-volume histogram analysis in predicting radiation pneumonitis in Hodgkin's lymphoma.
    Koh ES, Sun A, Tran TH, Tsang R, Pintilie M, Hodgson DC, Wells W, Heaton R, Gospodarowicz MK.
    Int J Radiat Oncol Biol Phys; 2006 Sep 01; 66(1):223-8. PubMed ID: 16904523
    [Abstract] [Full Text] [Related]

  • 19. Hodgkin's disease. A historical perspective.
    Avilés A, Díaz-Maqueo JC, Torras V, Ayala JR, Cortés HD.
    Arch Invest Med (Mex); 1991 Sep 01; 22(1):27-33. PubMed ID: 1726450
    [Abstract] [Full Text] [Related]

  • 20. Pediatric Hodgkin's disease.
    Oliapuram Jose B, Koerner P, Bertolone S, Patel CC, Spanos WJ, Paris KJ, Silverman CL, Yashar CM.
    J Ky Med Assoc; 2004 Mar 01; 102(3):104-6. PubMed ID: 15067795
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.